Search results for "Brain Neoplasm"

showing 10 items of 249 documents

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme

2008

Abstract Purpose: Cancer stem cells (CSC) are thought to represent the population of tumorigenic cells responsible for tumor development. The stem cell antigen CD133 identifies such a tumorigenic population in a subset of glioblastoma patients. We conducted a prospective study to explore the prognostic potential of CSC analysis in glioblastoma patients. Experimental Design: We investigated the relationship between the in vitro growth potential of glioblastoma CSCs and patient death or disease progression in tumors of 44 consecutive glioblastoma patients treated with complete or partial tumorectomy followed by radiotherapy combined with temozolomide treatment. Moreover, we evaluated by immun…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPathologyAC133 Antigen; Adult; Aged; Antigens CD; Brain Neoplasms; Female; Glioblastoma; Glycoproteins; Humans; Ki-67 Antigen; Male; Middle Aged; Multivariate Analysis; Neoplastic Stem Cells; Peptides; Prospective Studiesmedicine.medical_treatmentPopulationAntigens CDCancer stem cellInternal medicinemedicineHumansAC133 AntigenProspective StudiesAntigensProspective cohort studyeducationAgedGlycoproteinseducation.field_of_studyTemozolomideSettore MED/08 - ANATOMIA PATOLOGICAbusiness.industryBrain NeoplasmsHazard ratioMiddle AgedGliobastoma MultiformeCDRadiation therapyKi-67 AntigenOncologyMultivariate AnalysisNeoplastic Stem CellsImmunohistochemistryFemaleStem cellbusinessGlioblastomaPeptidesmedicine.drug
researchProduct

Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advan…

2020

Aim To investigate multivariable analyses for noninvasive association of the isocitrate dehydrogenase (IDH) mutational status in grade II and III gliomas including evaluation of T2 mapping-sequences. Methods Magnetic resonance imaging (MRI) examinations with histopathologically proven World Health Organization grade II and III gliomas were retrospectively enrolled. Multivariate receiver operating characteristics (ROC) analyses to associate IDH mutational status were performed containing quantitative T2 mapping analyses and qualitative characteristics (sex, age, localization, heterogeneity, oedema, necrosis and diameter). Relaxation times were calculated pixelwise by means of standardized RO…

OncologyAdultMalemedicine.medical_specialtyT2 mappingWorld Health OrganizationWorld health030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineMagnetic resonance imaging T2 mappingGliomaInternal medicinemedicineMutational statusHumansRadiology Nuclear Medicine and imagingNeoplastic DiseasesAgedRetrospective StudiesAged 80 and overbusiness.industryBrain NeoplasmsNon invasiveGeneral MedicineGliomaMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingIsocitrate DehydrogenaseMRI - Magnetic resonance imagingIsocitrate dehydrogenaseMutationFemaleNeurology (clinical)Neoplasm Gradingbusiness030217 neurology & neurosurgery
researchProduct

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT…

2021

Abstract Background Embryonal tumors with multilayered rosettes (ETMR) are highly aggressive tumors occurring in early childhood. Published clinical data refer to retrospective, heterogeneously treated cohorts. Here, we describe the outcome of patients treated according to the prospective P-HIT trial and subsequent HIT2000-interim-registry. Patients and methods Age-stratified treatment included carboplatin/etoposide induction, tandem high-dose chemotherapy (“CARBO/ETO + HDCT”), and response-stratified radiotherapy. Patients with centrally reviewed neuropathological and molecularly confirmed diagnosis of ETMR recruited within the P-HIT trial (2001-2011; n = 19), the HIT2000-interim-registry …

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinClinical InvestigationsImproved survival610 Medicine & healthBrain Neoplasms/drug therapyCentral Nervous System NeoplasmsHigh dose chemotherapychemistry.chemical_compoundCarboplatin/therapeutic useInternal medicinemedicineHigh-dose chemotherapyHumansNeuroectodermal Tumors Primitive1306 Cancer ResearchProspective StudiesChildOutcomeEtoposideRetrospective StudiesChemotherapyddc:618business.industryBrain NeoplasmsIncidence (epidemiology)IncidenceInfantInduction ChemotherapyNeoplasms Germ Cell and EmbryonalCarboplatinETMRRadiation therapyClinical trialClinical trial2728 Neurology (clinical)Oncologychemistry10036 Medical ClinicChild Preschool2730 OncologyNeurology (clinical)Antineoplastic Combined Chemotherapy Protocols/therapeutic usebusinessCarboplatin/etoposideNeoplasms Germ Cell and Embryonal/drug therapy
researchProduct

Prophylactic cranial irradiation in stage IV small cell lung cancer

2019

Background: Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial.Methods: We obtained a list of 13 European experts from both the European Society for Therapeutic Radiation Oncology (ESTRO) and the International Association for the Study of Lung Cancer (IASLC). The strategies in decision making for PCI in stage IV SCLC were collected. Decision trees were created representing these strategies. Analysis of consensus was performed with the objective consensus methodology.Results: The factors associated with the recommendation for the use of PCI included the fitness of the patient, young age…

OncologyMaleESTRO; Expert opinion; IASLC; PCI; Small cell lung cancer; Stage IV; Hematology; Oncology; Radiology Nuclear Medicine and ImagingLung Neoplasmsmedicine.medical_treatmentMedizin030218 nuclear medicine & medical imaging0302 clinical medicineQUALITY-OF-LIFENuclear Medicine and ImagingESTRO610 Medicine & healthStage IVHematologyBrain NeoplasmsRadiation OncologistsPCIHematologyMiddle AgedProgression-Free SurvivalExpert opinion030220 oncology & carcinogenesisFemaleTRIALNon small cellRadiologyAdultmedicine.medical_specialtyDecision Making03 medical and health sciencesInternal medicinemedicineHumansIASLCRadiology Nuclear Medicine and imagingLung cancerAgedNeoplasm StagingChemotherapySmall cell lung cancerbusiness.industryPatient Selectionmedicine.diseaseONCOLOGYSmall Cell Lung CarcinomaYoung ageConventional PCIProphylactic cranial irradiationCranial IrradiationbusinessStage ivRadiotherapy and Oncology
researchProduct

Cohort study of occupational cosmic radiation dose and cancer mortality in German aircrew, 1960-2014.

2020

ObjectivesTo determine cancer mortality compared with the general population and to examine dose-response relationships between cumulative occupational radiation dose and specific cancer outcomes in the German aircrew cohort.MethodsFor a cohort of 26 846 aircrew personnel, standardised mortality ratios (SMR) were calculated. Dose-response analyses were carried out using Poisson regression to assess dose-related cancer risks for the period 1960–2014. Exposure assessment comprises recently available dose register data for all cohort members and newly estimated retrospective cabin crew doses for 1960–2003.ResultsSMR for all-cause, specific cancer groups and most individual cancers were reduced…

OncologyMalemedicine.medical_specialtyNeoplasms Radiation-InducedPopulationRadiation DosageEffective dose (radiation)Cohort Studies03 medical and health sciencessymbols.namesake0302 clinical medicineInternal medicineGermanyOccupational ExposuremedicineHumansPoisson regressioneducationMelanomaAgededucation.field_of_studyCumulative dosebusiness.industryBrain NeoplasmsPublic Health Environmental and Occupational HealthDose-Response Relationship RadiationMiddle Aged030210 environmental & occupational healthOccupational Diseases030220 oncology & carcinogenesisRelative riskCohortsymbolsAircrewFemalebusinessCosmic RadiationCohort studyOccupational and environmental medicine
researchProduct

A Pooled Analysis of Extremely Low-Frequency Magnetic Fields and Childhood Brain Tumors

2010

Pooled analyses may provide etiologic insight about associations between exposure and disease. In contrast to childhood leukemia, no pooled analyses of childhood brain tumors and exposure to extremely low-frequency magnetic fields (ELF-MFs) have been conducted. The authors carried out a pooled analysis based on primary data (1960–2001) from 10 studies of ELF-MF exposure and childhood brain tumors to assess whether the combined results, adjusted for potential confounding, indicated an association. The odds ratios for childhood brain tumors in ELF-MF exposure categories of 0.1–<0.2 μT, 0.2–<0.4 μT, and ≥0.4 μT were 0.95 (95% confidence interval: 0.65, 1.41), 0.70 (95% CI: 0.40, 1.22), and 1.1…

Oncologymedicine.medical_specialtyNeoplasms Radiation-InducedChildhood leukemiaEpidemiologyBrain tumorGlobal HealthCentral nervous system diseaseElectromagnetic FieldsRisk FactorsInternal medicineEpidemiologymedicineHumansChildBrain Neoplasmsbusiness.industryIncidenceConfoundingOdds ratiomedicine.diseaseConfidence intervalSurgeryMeta-analysisbusinessSystematic Reviews and Meta- and Pooled AnalysesAmerican Journal of Epidemiology
researchProduct

Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study

2019

Background Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by a heterogeneous and abnormal vascularity. Subtypes of vascular habitats within the tumor and edema can be distinguished: high angiogenic tumor (HAT), low angiogenic tumor (LAT), infiltrated peripheral edema (IPE), and vasogenic peripheral edema (VPE). Purpose To validate the association between hemodynamic markers from vascular habitats and overall survival (OS) in glioblastoma patients, considering the intercenter variability of acquisition protocols. Study Type Multicenter retrospective study. Population In all, 184 glioblastoma patients from seven European centers participating in the NCT03439332 c…

Oncologymedicine.medical_specialtyVascularityContrast MediaPerfusion DSC030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalHumansRadiology Nuclear Medicine and imagingOverall survivalRetrospective StudiesBrain Neoplasmsbusiness.industryPrognosismedicine.diseaseMagnetic Resonance ImagingMulticenter studyPeer reviewddc:616.8Multicenter studyglioblastoma multicenter study overall survival perfusion DSC vascularitybusinessGlioblastomaGlioblastoma
researchProduct

The Role of Medicinal Mushrooms in Brain Cancer Therapies: Review.

2021

Medicinal mushrooms are considered an unlimited source of polysaccharides (mainly β-glucans) and polysaccharide-protein complexes and possess various immunological and anticancer properties. In addition, their use in integrative medicine leads to a clear reduction of side effects in patients undergoing chemotherapy or radiotherapy. The literature reports a number of beneficial effects of using mushrooms as health supplements in patients affected by high-grade glioma. The effects of medicinal mushrooms on side effects in patients with brain cancer and a case study report are also described in this review.

Oncologymedicine.medical_specialtymedicine.medical_treatmentMEDLINEApplied Microbiology and BiotechnologyBrain cancerStudy reportPolysaccharidesInternal medicineGliomaDrug DiscoverymedicineHumansIn patientintegrative therapies brain cancer glioblastoma medicinal mushrooms mycotherapeutic supportPharmacologyChemotherapybusiness.industryBrain Neoplasmsmedicine.diseaseRadiation therapySettore BIO/03 - Botanica Ambientale E ApplicataDietary SupplementsIntegrative medicinebusinessAgaricalesInternational journal of medicinal mushrooms
researchProduct

Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression

2012

Wnt modulates glioma vascularization by regulating PDGF-B expression.

PathologyAngiogenesisCentral Nervous System NeoplasmsMice0302 clinical medicineImmunology and AllergyWnt Signaling Pathwaybeta Catenin0303 health sciencesbiologyNeovascularization PathologicBrain NeoplasmsWnt signaling pathwayIntracellular Signaling Peptides and ProteinsForkhead Transcription FactorsGliomaProto-Oncogene Proteins c-sis3. Good healthmedicine.anatomical_structureBlood-Brain Barrier030220 oncology & carcinogenesiscardiovascular systemIntercellular Signaling Peptides and ProteinsFemalemedicine.medical_specialtyBeta-cateninEndotheliumImmunologyNotch signaling pathwayMice NudeWnt1 ProteinMural cellArticle03 medical and health sciencesGliomamedicineAnimalsHumansddc:610neoplasms030304 developmental biologyAdaptor Proteins Signal TransducingCalcium-Binding ProteinsMembrane Proteinsmedicine.diseaseXenograft Model Antitumor Assaysnervous system diseasesDKK1Cancer researchbiology.proteinEndothelium VascularNeoplasm Grading
researchProduct

Immunoreactivity using anti-ERG monoclonal antibodies in sarcomas is influenced by clone selection.

2014

The aim of the present study was to explore ERG immunoreactivity in a series of sarcomas, GIST and malignant rhabdoid tumor (MRT), considering the not fully elucidated specificity and sensitivity of this antibody. Paraffin-embedded tissue microarrays from those tumors were stained with anti-ERG against the C-terminus [(EPR3864(2)] and N-terminus (Clone 9FY). EPR3864(2) was positive in almost all angiosarcomas, and MRT.GIST were positive in a large proportion of cases (38.4%), and more than half the synovial sarcomas (52.7%) revealed EPR3864(2) staining. Several chondrosarcomas, osteosarcomas, rhabdomyosarcoma and Ewing's sarcoma family of tumors (ESFT) presented EPR3864(2) expression in a l…

Pathologymedicine.medical_specialtyGastrointestinal Stromal TumorsClone (cell biology)BiologySensitivity and SpecificityPathology and Forensic MedicineFusion geneTranscriptional Regulator ERGmedicineHumansRhabdomyosarcomaRhabdoid TumorRetrospective StudiesTissue microarrayBrain NeoplasmsSarcomasEwing's sarcomaAntibodies MonoclonalEwing's sarcomaSarcomaCell Biologymedicine.diseaseImmunohistochemistrySynovial sarcomaKidney NeoplasmsERGTrans-ActivatorsImmunohistochemistrySarcomaPathology, research and practice
researchProduct